We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » German Court Rules for ResMed in Patent Infringement Lawsuit

German Court Rules for ResMed in Patent Infringement Lawsuit

July 29, 2014

San Diego, Calif.-based ResMed won another round in its patent infringement battle against Apex Medical, securing a permanent injunction from that German court that prevents the Taiwanese devicemaker from selling its breathing therapy headgear in that country.

The ruling comes on the heels of an import ban imposed by the U.S. International Trade Commission on continuous positive airway pressure machines marketed by Apex and its U.S. distributor, Medical Depot, in response to a ResMed complaint.

The German injunction, by the Regional Court of Munich, applies to the Apex WiZARD 210 and 220 CPAP sleep breathing therapy face masks. According to ResMed, Apex must forfeit any inventory it has in Germany and pay undisclosed damages. The same court issued temporary injunctions against Apex last November.

Apex said Tuesday that it will appeal the German judgment.

ResMed has filed additional lawsuits in the German court seeking damages and permanent injunctions on the Apex iCH and XT Fit CPAP devices. Those trials are slated for sometime this fall, the company said.

Spokeswoman Gretchen Griswold told Device Daily Bulletin that ResMed will continue to evaluate where its CPAP patent is being infringed on a market-by-market basis.

The company is pleased that its intellectual property continues to be validated by courts both within and outside the U.S., Griswold said. “For 25 years, we have pioneered innovations that represent giant leaps forward in comfortable, patient-centric therapy products for sleep-disordered breathing, a condition where comfort is the critical factor in keeping patients on therapy. We are concerned about look-alike products that don’t reflect that same care for the patient that ResMed products do.” — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Medical Devices Commercial Operations

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing